ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
SSX1 and TRIM58 expression stratifies lung squamous cell carcinoma by tumor immune microenvironment characteristics and informs potential immunotherapy responsiveness.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung squamous cell carcinoma (LUSC) remains a therapeutic challenge with limited biomarkers. The tumor immune microenvironment (TIME) is crucial for progression and immunotherapy response. Because SSX1 and TRIM58 emerged as significant independent prognostic factors, this study investigated their combined prognostic and immunological significance in LUSC.
methodsTranscriptomic and clinical data from LUSC patients in The Cancer Genome Atlas (TCGA) were analyzed. A prognostic model was constructed, and consensus clustering was performed based on SSX1 and TRIM58 expression. Differences in survival, immune cell infiltration (assessed by CIBERSORT and ssGSEA), immune checkpoint expression, and ESTIMATE scores were evaluated. RT-qPCR on five paired LUSC and normal tissues validated key findings.
resultsPatients were stratified into two clusters: Cluster 1 (high SSX1/low TRIM58) and Cluster 2 (low SSX1/high TRIM58). RT-qPCR confirmed SSX1 upregulation and TRIM58 downregulation in tumors. Despite high TRIM58, Cluster 2 exhibited significantly poorer overall survival. This cluster demonstrated a more inflamed but immunosuppressive TIME, characterized by significantly increased infiltration of diverse immune cells (including activated T cells and M2 macrophages), higher Immune/ESTIMATE scores, and elevated expression of multiple immune checkpoint molecules (including PD-1, PD-L1, and CTLA-4).
conclusionThe expression of SSX1 and TRIM58 defines two distinct LUSC subtypes with contrasting TIME landscapes and clinical outcomes. The paradoxical combination of immune activation and poor survival in Cluster 2 highlights a potentially dysfunctional immune state. This two-gene signature could serve as a valuable biomarker for prognostic stratification and might offer insights into personalized immunotherapy strategies in LUSC.
Indexed as
Identifiers
42030005What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.